Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials

Japanese Journal of Clinical Oncology

Volumn 35, Issue 10, 2005, Pages 601-606

  Ishii, Hiroshi ^a   Furuse, Junji ^a   Nakachi, Kouhei ^a   Suzuki, Ei Ichiro ^a   Yoshino, Masahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Computed tomography; Measurement; Pancreatic neoplasm; RECIST; Response

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NK 911;

ADULT; ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 27944436614     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi151     Document Type: Review

References (18)

1. Aoki K, Okada S, Moriyama N, Ishii H, Nose H, Yoshimori M, et al. Accuracy of computed tomography in determining pancreatic cancer tumor size. Jpn J Clin Oncol 1994;24:85-7.
2. Furukawa H, Takayasu K, Mukai K, Inoue K, Kosuge T, Ushio K. Computed tomography of pancreatic adenocarcinoma: Comparison of tumor size measured by dynamic computed tomography and histopathologic examination. Pancreas 1996;13:231-5.
3. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1993; 78:654-63.
4. Okada S. Non-surgical treatments of pancreatic cancer. Int J Clin Oncol 1999;4:257-66.
5. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92:569-77.
6. El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 2003;21:2920-5.
7. Arends JJ, Sleeboom HP, Leys MB, Ten Bokkel Huinink D, de Jong RS, Smit JM, et al. A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. Br J Cancer 2005; 92:445-8.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;63:457-81.
10. Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: Report of four cases. Lung Cancer 2004;43:71-4.
11. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004;43:63-9.
12. Koizumi W, Kurihara M, Tanabe S, Kondo I, Yamazaki I, Nonaka M, et al. Advantages of Japanese response criteria for estimating the survival of patients with primary gastric cancer. Gastric Cancer 1999;2:14-9.
13. Yoshida S, Miyata Y, Ohtsu A, Boku N, Shirao K, Shimada Y. Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 2000;3:128-33.
14. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516-20.
15. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-7.
16. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA, Combined 5-fluorourail and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2: 865-7.
17. The Gastrointestinal Tumor Study Group. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 1981;48:1705-10.
18. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.